Table 2.
The Distribution of Frequencies of VDR Genotype and Haplotype Among Controls and Different Clinical Stages of Chronic HCV Infection
| Con (n = 100) | CH (n = 201) | LC (n = 47) | HCC (n = 92) | |
|---|---|---|---|---|
| BsmI (rs1544410) | ||||
| TT | 0 (0%) | 0 (0%) | 0 (0%) | 0 (%) |
| TC | 11 (11%) | 13 (6%) | 6 (13%) | 7 (8%) |
| CC | 89 (89%) | 188 (94%) | 41 (87%) | 85 (92%) |
| T vs. C allele | 11:189 | 13:389 | 6:88 | 7:177 |
| ApaI (rs7975232) | ||||
| CC | 55 (55%)a | 102 (51%)b | 24 (51%)c | 65 (71%)abc |
| CA | 40 (40%)d | 82 (41%)e | 19 (40%) | 24 (26%)de |
| AA | 5 (5%) | 17 (8%) | 4 (9%) | 3 (3%) |
| C vs. A allele | 150:50f | 286:116g | 67:27h | 154:30fgh |
| TaqI (rs731236) | ||||
| GG | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| AG | 14 (14%) | 15 (7%) | 7 (15%) | 6 (7%) |
| AA | 86 (86%) | 186 (93%) | 40 (85%) | 86 (93%) |
| G vs. A allele | 14:186 | 15:387 | 7:87 | 6:178 |
| BsmI–ApaI–TaqI | ||||
| TAG (BaT) | 10 (10%) | 12 (6%) | 5 (11%) | 5 (5%) |
| CCA (bAt) | 54 (54%)i | 102 (51%)j | 24 (51%)k | 64 (70%)ijk |
| CAA (bat) | 31 (31%) | 83 (41%)l | 15 (32%) | 21 (23%)l |
| CAG (baT) | 4 (4%) | 3 (1%) | 2 (4%) | 0 (0%) |
| TAA (Bat) | 0 (0%) | 1 (1%) | 1 (2%) | 1 (1%) |
| TCG (BAT) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| TCA (BAt) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
| CCA vs. TAG & CAA | 54:41m | 102:95n | 24:20 | 64:26mn |
Data are expressed as number (percentage). P-value by x2 test or Fisher’s exact test;
Abbreviation: VDR, vitamin D receptor; Con: healthy control; CH: chronic hepatitis; LC: liver cirrhosis; HCC: hepatocellular carcinoma.
a
P = 0.027; bP = 0.001; cP = 0.026; dP = 0.047; eP = 0.018; fP = 0.044; gP = 0.001; hP = 0.019; iP = 0.037; jP = 0.003; kP = 0.041; lP = 0.002; mP = 0.048; nP = 0.002